Sun Pharma Reports Q2 Profit Decline Amid Revenue Growth and Organon Acquisition Plans
Sun Pharmaceutical Industries reported a 36% year-on-year decline in Q2 net profit to ₹1,988.53 crore, mainly due to exceptional expenses from its proposed Organon acquisition and US litigation settlements. Despite this, consolidated revenue rose nearly 12% to ₹16,198.71 crore, driven by growth in India, emerging markets, and specialty medicines like Ilumya. The company expects medium-term growth from its innovative portfolio and biosimilars from the Organon deal. Analysts maintain buy ratings, citing strong market positions and growth prospects despite near-term US generics challenges.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 40/100.
Outlets measured: moneycontrol, economictimes, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–72/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 1 Nov, 12:14 pm. Other outlets followed.